Burtness, Barbara

Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial

Seiwert, T. Y., Burtness, B., Mehra, R., Weiss, J., Berger, R., Eder, J. P., Heath, K., McClanahan, T., Lunceford, J., Gause, C., et al. (2016) · The Lancet Oncology

Cancer Immunotherapy and BiomarkersHead and Neck Cancer Studies

Cited by 1,745

Abstract P078: Aurora A kinase inhibition with VIC-1911 overcomes intrinsic and acquired resistance to KRASG12C inhibition in KRAS(G12C)-mutated lung cancer

Lee, J. W., Kim, S., Yang, C., & Burtness, B. (2021) · Molecular Cancer Therapeutics

Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling

Cited by 5

A phase 1a/1b study of aurora kinase A inhibitor VIC-1911 as monotherapy and in combination with sotorasib for the treatment of KRAS G12C-mutant non–small-cell lung cancer.

Goldberg, S. B., Punekar, S. R., Velcheti, V., Riess, J. W., Scilla, K. A., Carlisle, J. W., Politi, K. A., Lee, J. W., Myers, T. J., Paradiso, L. J., et al. (2023) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling

Cited by 5